CERo Therapeutics Holdings, Inc. (CERO)

NASDAQ: CERO · Real-Time Price · USD

8.28

+0.31 (3.89%)

At close: Aug 13, 2025, 4:00 PM

8.16

-0.12 (-1.39%)

Pre-market: Aug 14, 2025, 9:11 AM EDT

CERO Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	9.89	10.73	3.95	2.84	0.43
Research & Development	6.71	5.47	3.72	-	-
Other Operating Expenses	-	-	-	0.06	0.14
Operating Expenses	16.75	16.2	7.68	2.91	0.57
Operating Income	-16.75	-16.2	-7.68	-2.91	-0.57
Interest & Investment Income	0.04	0.03	0.14	2.84	-
Other Non Operating Income (Expenses)	2.41	4.53	0.24	-	-
EBT Excluding Unusual Items	-14.31	-11.64	-7.3	-0.07	-0.57
Gain (Loss) on Sale of Investments	-	-	-	-	-0
Other Unusual Items	3.2	3.34	0.01	-	-
Pretax Income	-11.11	-8.3	-7.29	-0.07	-0.57
Income Tax Expense	-	-	-	0.6	-0.03
Net Income	-11.11	-8.3	-7.29	-0.67	-0.54
Preferred Dividends & Other Adjustments	3.13	2.78	-	-	36.16
Net Income to Common	-14.24	-11.09	-7.29	-0.67	-36.71
Shares Outstanding (Basic)	0	0	-	0	-
Shares Outstanding (Diluted)	0	0	-	0	-
EPS (Basic)	-241.81	-434.46	-	-59.38	-
EPS (Diluted)	-241.81	-434.46	-	-59.38	-
EBITDA	-16.35	-15.76	-7.21	-	-
D&A For EBITDA	0.4	0.44	0.46	-	-
EBIT	-16.75	-16.2	-7.68	-2.91	-0.57

Updated Nov 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q